BiotechTube

Glassia

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
15
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute-graft-versus-host Disease

Conditions

Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease, Graft-versus-host-disease, Graft Vs Host Disease, Alpha 1-Antitrypsin Deficiency, Alpha-1 Proteinase Inhibitor, Alpha-1 Protease Inhibitor Deficiency, Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant

Trial Timeline

— → —

NCT ID
NCT03172455

About Glassia

Glassia is a pre-clinical stage product being developed by Kamada for Acute-graft-versus-host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03172455. Target conditions include Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease, Graft-versus-host-disease.

Hype Score Breakdown

Clinical
5
Activity
2
Company
2
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT03172455Pre-clinicalCompleted

Competing Products

2 competing products in Acute-graft-versus-host Disease

See all competitors
ProductCompanyStageHype Score
EQ001 + EQ001 PlaceboBioconPhase 1/2
41
AAT + PlaceboCSLPhase 2/3
64

Other Products from Kamada

CytogamApproved
77
Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three monthsApproved
77
KamRAB - HRIGPhase 3
69
Alpha 1-Antitrypsin + PlaceboPhase 3
69
Active rabies vaccine (US-FDA approved)Phase 2/3
57